ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2067

Pre-Transplant Sarcopenia Does Not Predict Graft Function or Mortality in Kidney Transplantation

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Norris, Taylor, University of Kansas Medical Center, Kansas City, Kansas, United States
  • Montgomery, Neal, University of Kansas Medical Center, Kansas City, Kansas, United States
  • Fishback, Shelby, University of Kansas Medical Center, Kansas City, Kansas, United States
  • Cibrik, Diane Marie, University of Kansas Medical Center, Kansas City, Kansas, United States
  • Gupta, Aditi, University of Kansas Medical Center, Kansas City, Kansas, United States
Background

Sarcopenia is common in end stage kidney disease (ESKD), and is associated with increased risk of cardiovascular events and mortality. The association between pre-transplant sarcopenia and post-transplant outcomes is unknown.

Methods

We conducted a single-center retrospective study to evaluate the association between pre-transplant psoas muscle cross-sectional area at level of L4 and post-transplant outcomes; change in graft function, length of hospitalization, rehospitalization at 30- and 90-days post-transplant, graft loss, and mortality.

Results

Of the 573 patients with pre-transplant CT images, 465 received kidney transplant (KT) alone, 71 received simultaneous liver-kidney transplantation (SLK), and 37 received simultaneous pancreas-kidney (SPK) transplantation. Pre-transplant psoas muscle cross sectional area was associated with longer hospitalization in KT alone and SPK transplants, but not with post-transplant graft function, rehospitalization rates or mortality (Table 1).

Conclusion

Unlike ESKD patients on dialysis, pre-transplant psoas muscle cross-sectional area is not associated with adverse post-transplant outcomes. Thus, sarcopenia should not be an exclusion criterion for transplant eligibility.

Cox proportional hazard models (adjusted for age, sex, race and diabetes) for normalized psoas cross sectional area and post-transplant outcomes.
 Exp(Estimate) (95%CI - HR)
ModelKT aloneSLKSPK
Change in eGFR-0.005
(-0.01, 0.0009)
-0.01
(-0.03, 0.002)
-0.02
(-0.05, 0.0008)
Graft Loss0.999
(0.998, 1.001)
0.99
(0.994, 1.004)
1.004
(0.996, 1.013)
Length of Hospitalization-0.003
(-0.005, -0.0007)
-0.007
(-0.02, 0.004)
0.03
(0.01, 0.05)
30-day rehospitalization1
(0.999, 1.001)
1
(0.998, 1.002)
0.999
(0.996, 1.003)
90-day rehospitalization1.002
(0.9996, 1.0001)
1
(0.998, 1.002)
0.999
(0.996, 1.002)
Mortality0.99
(0.996, 1.001)
0.99
(0.995, 1.002)
N/A